Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pliant Therapeutics, Inc.

1.70
0.0000
Volume:598.22K
Turnover:988.10K
Market Cap:104.36M
PE:-0.47
High:1.70
Open:1.70
Low:1.61
Close:1.70
Loading ...

Pliant Therapeutics downgraded to Neutral from Overweight at JPMorgan

TipRanks
·
11 Feb

Sector Update: Health Care Stocks Retreat Monday Afternoon

MT Newswires Live
·
11 Feb

Pliant Therapeutics Pauses Enrollment in BEACON-IPF Trial, Shares Take Steep Dive

GuruFocus.com
·
11 Feb

Pliant Therapeutics Shares Tumble Amid Analyst Downgrades Following Study Suspension

MT Newswires Live
·
11 Feb

Pliant Therapeutics Cut to Hold From Buy by Canaccord Genuity

Dow Jones
·
10 Feb

Pliant Therapeutics Cut to Equal-Weight From Overweight by Wells Fargo

Dow Jones
·
10 Feb

Sector Update: Health Care Stocks Flat to Edging Higher Pre-Bell Monday

MT Newswires Live
·
10 Feb

Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues

Benzinga
·
10 Feb

Top Premarket Decliners

MT Newswires Live
·
10 Feb

BUZZ-Pliant Therapeutics slumps as it halts enrollment in lung disease mid-stage trial

Reuters
·
10 Feb

Pliant Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
10 Feb

Piper Sandler Remains a Buy on Pliant Therapeutics (PLRX)

TIPRANKS
·
10 Feb

Pliant Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
10 Feb

Pliant Therapeutics Shares Fall on Drug Trial Pause After Safety Board Review

Dow Jones
·
10 Feb

RBC Downgrades Pliant Therapeutics to Sector Perform From Outperform, Cuts Price Target to $4 From $45, Keeps Speculative Risk

MT Newswires Live
·
10 Feb

Pliant Therapeutics Suspends Enrollment in Phase 2b Idiopathic Pulmonary Fibrosis Trial

MT Newswires Live
·
10 Feb

BUZZ-Pliant pauses enrollment for lung disease treatment trial

Reuters
·
08 Feb

Pliant Therapeutics trading resumes

TIPRANKS
·
08 Feb

Pliant Therapeutics pauses enrollment, dosing in BEACON-IPF Phase 2b trial

TIPRANKS
·
08 Feb

BRIEF-Pliant Therapeutics Provides Update On BEACON-IPF, A Phase 2B/3 Trial In Patients With Idiopathic Pulmonary Fibrosis

Reuters
·
08 Feb